<DOC>
	<DOCNO>NCT02639221</DOCNO>
	<brief_summary>The principal aim study obtain safety tolerability data PXT002331 administer orally single multiple dos healthy subject .</brief_summary>
	<brief_title>A Phase I , Double Blind , Placebo Controlled , First Human , Single Multiple Ascending Oral Dose , Safety , Tolerability Pharmacokinetic Study Healthy Male Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>1 . Subjects ; 1.1. male female non childbearing potential 1.2 . For female , non childbearing potential defined follow : permanently sterile follow hysterectomy , bilateral salpingectomy , bilateral oophorectomy , confirm tubal occlusion ( tubal ligation ) postmenopausal , define least 1 year post cessation menses ( without alternative medical cause ) 1.3. ethnic origin 1.4. 18 60 year age , inclusive 2 . Subjects 2.1. body mass index ( BMI ) 18.0 kg/m2 32.0 kg/m2 , inclusive 2.2. body weight 50 kg 100 kg , inclusive 3 . Subjects good health , determine ; 3.1. medical history 3.2. physical examination 3.3. vital sign assessment 3.4 . 12 lead ECG 24 hour Holter Monitoring 3.5. clinical laboratory evaluation ( congenital non haemolytic hyperbilirubinaemia acceptable ) 4 . Subjects give write informed consent participate study abide study restriction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>